Go to the list of all blogs
Allana's Avatar
published in Blogs
May 10, 2019
TickeronGET DAILY SIGNALS
Drug prices to be included in TV ads under new rule

Drug prices to be included in TV ads under new rule

The Department of Health and Human Services announced a new policy to improve transparency in the pharmaceutical industry.

Starting this summer, TV commercials for prescription drugs covered by Medicaid or Medicare must mention the list price if it exceeds $35 for the standard treatment course or monthly supply. The policy has no enforcement mechanism but depends on companies suing rivals that violate the standard. The HHS will also publish a list of drugs with non-compliant ads.

“Patients who are struggling with high drug costs are in that position because of the high list prices that drug companies set,” HHS Secretary Alex Azar said in a press release. “Making those prices more transparent is a significant step in President Trump’s efforts to reform our prescription drug markets and put patients in charge of their own healthcare.”

Related Ticker: FTXH

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


FTXH in upward trend: 10-day moving average crossed above 50-day moving average on October 20, 2026

The 10-day moving average for FTXH crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on FTXH as a result. In 66 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

The Moving Average Convergence Divergence (MACD) for FTXH just turned positive on October 15, 2026. Looking at past instances where FTXH's MACD turned positive, the stock continued to rise in 39 of 48 cases over the following month. The odds of a continued upward trend are 81%.

FTXH moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where FTXH advanced for three days, in 252 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

The Aroon Indicator entered an Uptrend today. In 226 of 278 cases where FTXH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.

Bearish Trend Analysis

The 10-day RSI Indicator for FTXH moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 26 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 67 cases where FTXH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 75%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTXH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.

FTXH broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN).

Industry description

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq U.S. Smart Pharmaceuticals TM Index. The fund will normally invest at least 80% of its net assets (including investment borrowings) in the securities that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and ranking. It is non-diversified.

Market Cap

The average market capitalization across the First Trust Nasdaq Pharmaceuticals ETF (FTXH) ETF is 77.04B. The market cap for tickers in the group ranges from 3.62B to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is ELVN at 3.62B.

High and low price notable news

The average weekly price growth across all stocks in the First Trust Nasdaq Pharmaceuticals ETF (FTXH) ETF was 44%. For the same ETF, the average monthly price growth was 75%, and the average quarterly price growth was 434%. MRNA experienced the highest price growth at 15%, while CAI experienced the biggest fall at -27%.

Volume

The average weekly volume growth across all stocks in the First Trust Nasdaq Pharmaceuticals ETF (FTXH) ETF was 9%. For the same stocks of the ETF, the average monthly volume growth was 38% and the average quarterly volume growth was -23%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 50
Price Growth Rating: 41
SMR Rating: 67
Profit Risk Rating: 56
Seasonality Score: 18 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
The central stock price target of $100 is the arithmetic mean of the verified analyst price targets reviewed; major aggregators report a similar consensus near $99–$102, with a wide range from roughly $60 to $150. With the stock trading near $53, reaching $100 would require a gain of approximately 88% — a very large move from current levels.
The central $29 price target is the arithmetic mean of three verified, current analyst targets, rounded from an underlying average of about $28.67. With Groupon, Inc. (GRPN) recently trading near $16, reaching $29 would require a gain of roughly 80%, a very large move.
ON Semiconductor shares plunged -21.19% to $93.58 during Friday's regular session, extending a steep premarket selloff that began after Thursday's close. The primary catalyst was the announcement of a $7 billion all-stock acquisition of Synaptics (SYNA), with investors reacting negatively to significant shareholder dilution and the deal's strategic fit.
Exascale Labs Holdings is scaling a software-defined GPU (graphics processing unit) compute platform, with fiscal 2026 revenue rising 111% year over year to $14.8 million. A roughly $300 million qualified customer pipeline is the central forward-looking metric, though it has yet to be converted into signed contracts or recognized revenue.
NFT Limited (MI) rebounded +21.35% during regular market hours, trading near $1.08 versus the prior session's $0.89 close. The gain follows a steep -41.89% plunge the prior session after the company priced a dilutive 1 million-unit direct offering at $1.00 per unit.